Related Experiment Video
Updated: Jan 20, 2026

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
Published on: October 10, 2025
How I treat ALK-positive non-small cell lung cancer
Michael G McCusker1, Alessandro Russo2, Katherine A Scilla1
1University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, USA.
Abstract:
Since the discovery of anaplastic lymphocyte kinase (ALK) rearrangement in non-small cell lung cancer (NSCLC) and subsequent development of increasingly effective and central nervous system (CNS)-penetrant first-generation, second-generation and third-generation ALK tyrosine kinase inhibitors (TKIs), the landscape of resistance mechanisms and treatment decisions has become increasingly complex. Tissue and/or plasma-based molecular tests can identify not only the rearrangement proper but also common resistance mechanisms to guide decision-making for further lines of treatment. However, frequently encountered questions exist regarding how to diagnosis ALK rearrangement, how to select a first-line ALK TKI, how to diagnose and manage ALK TKI resistance, how to control CNS disease and how to handle failure of ALK inhibition. Herein, we attempt to answer these questions through the evidence-based interpretation of studies on ALK-rearranged NSCLC combined with experience gained from our institution. The authors also propose a therapeutic algorithm for the management of this complex and highly treatable disease to assist clinicians globally in the treatment of patients with ALK-positive NSCLC.
Insights
Anaplastic Lymphoma Kinase (ALK) rearrangement in non-small cell lung cancer (NSCLC) presents complex treatment challenges. This study provides an evidence-based algorithm to guide diagnosis, TKI selection, resistance management, and CNS disease control for ALK-positive NSCLC.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Anaplastic Lymphoma Kinase (ALK) rearrangement is a key driver in a subset of non-small cell lung cancer (NSCLC).
- The development of ALK tyrosine kinase inhibitors (TKIs) has revolutionized treatment, but resistance mechanisms and central nervous system (CNS) disease pose significant challenges.
- Molecular testing is crucial for identifying ALK rearrangements and resistance mutations to guide therapy.
Purpose of the Study:
- To address complex clinical questions regarding the diagnosis and management of ALK-rearranged NSCLC.
- To provide evidence-based guidance on selecting first-line ALK TKIs and managing treatment resistance.
- To propose a therapeutic algorithm for optimizing patient care and outcomes in ALK-positive NSCLC.
Main Methods:
- Comprehensive review and evidence-based interpretation of existing studies on ALK-rearranged NSCLC.
- Integration of clinical experience from the authors' institution.
- Development of a therapeutic algorithm based on current evidence and clinical practice.
Main Results:
- Molecular testing identifies ALK rearrangement and common resistance mechanisms, informing treatment decisions.
- Effective strategies exist for managing CNS disease and overcoming ALK TKI resistance.
- A proposed algorithm offers a structured approach to the multifaceted management of ALK-positive NSCLC.
Conclusions:
- ALK-rearranged NSCLC requires a nuanced management strategy due to evolving resistance patterns and CNS involvement.
- Molecular diagnostics play a pivotal role in guiding personalized treatment selection and adaptation.
- The proposed therapeutic algorithm aims to standardize and improve clinical decision-making for ALK-positive NSCLC patients globally.
Related Concept Videos
Chromatin Position Affects Gene Expression
Topologically Associated Domains (TADs)
The 3-dimensional positioning of chromatin in the nucleus influences the...
Position-effect Variegation
Lung Capacity
Position and Displacement
Serial Position Effect
Positive Regulator Molecules

